Table 4.
Baseline demographics and characteristics of patients in the alirocumab group with ≥ 2 consecutive LDL-C values < 15 mg/dL and propensity score-matched patients from the placebo group
|
All (N = 3128) |
Alirocumab (N = 782) |
Placebo (N = 2346) |
|
|---|---|---|---|
| Age, years | 58.8 ± 9.5 | 58.9 ± 9.4 | 58.7 ± 9.5 |
| < 65 | 2243 (71.7) | 557 (71.2) | 1686 (71.9) |
| 65 to < 75 | 711 (22.7) | 184 (23.5) | 527 (22.5) |
| ≥ 75 | 174 (5.6) | 41 (5.2) | 133 (5.7) |
| Male | 2526 (80.8) | 645 (82.5) | 1881 (80.2) |
| Race | |||
| White | 1928 (61.6) | 461 (59.0) | 1467 (62.5) |
| Asian | 951 (30.4) | 253 (32.4) | 698 (29.8) |
| Other/unknown | 249 (8.0) | 68 (8.7) | 181 (7.7) |
| Hispanic or Latino | 752 (24.0) | 192 (24.6) | 560 (23.9) |
| Weight, kg | 77.9 ± 16.5 | 76.9 ± 16.6 | 78.2 ± 16.4 |
| BMI, kg/m2 | 27.3 ± 4.5 | 27.2 ± 4.5 | 27.4 ± 4.4 |
| ≥ 30 kg/m2 | 784 (25.1) | 191 (24.4) | 593 (25.3) |
| Region | |||
| Asia | 919 (29.4) | 240 (30.7) | 679 (28.9) |
| South America | 710 (22.7) | 178 (22.8) | 532 (22.7) |
| Eastern Europe | 665 (21.3) | 157 (20.1) | 508 (21.7) |
| Western Europe | 343 (11.0) | 81 (10.4) | 262 (11.2) |
| North America | 336 (10.7) | 85 (10.9) | 251 (10.7) |
| Rest of world | 155 (5.0) | 41 (5.2) | 114 (4.9) |
Data are presented as mean ± standard deviation or n (%)
BMI Body mass index